Finally, there’s a challenge to Rivers‘ EGDT.
Early goal-directed therapy provides significant benefits with respect to outcome in patients with severe sepsis and septic shock.
But now some doctors are questioning the rigor of the research behind it, which was done at a single hospital. Adding to the concerns: That hospital held patents on a medical device critical to the therapy. And one of the groups that later endorsed the treatment had financial backing from the maker of the device.
A large NIH-funded study to re-evaluate Dr. Rivers’s early goal-directed therapy is under way at the University of Pittsburgh Medical Center. In contrast to the one-hospital study that launched the therapy, this one will include up to two dozen hospitals. Another multicenter study of the therapy is planned in Australia.
Let’s see antibiotics within four hours for CAP—now not so scientific; will how we treat sepsis be found to be as equally “scientific”?
